← Leaderboards
Brian Till
Fred Hutchinson Cancer Research Center
$4,139,904
Attributed
$4,710,583
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1M · FY2013–23$2M$1.5M$1M$500K$0
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
Funding mix
By agency
NIH$4,710,583 · 3
By mechanism
R01$4,023,703 · 2
K23$686,880 · 1
Top collaborators
- Damian J. Green3 shared
Most similar at Fred Hutchinson Cancer Research Center
Same institution · by research overlap
- Oliver W. Press$23,607,906
- David G Maloney$3,575,748
- Brenda Marie Sandmaier$22,185,663
- Rainer F. Storb$23,835,935
- Christopher S Carlson$5,755,749
Others in their field
Top investigators on “Non-Hodgkin&Apos”
- Trudy M Forte · University Of Calif-Lawrenc Berkeley Lab$109,354
Research focus
Non-Hodgkin&AposRelapseTumorFundingResponseS LymphomaPre-ClinicalDesignClinical TrialsMs4a1 GeneResearch PersonnelRefractory DiseaseImmunotherapyAutologousGenerationsAreaPredispositionChimeric Antigen ReceptorCellular BiologyNeoplastic CellEffective TherapyCellsAdoptive ImmunotherapyRefractory
Grant awards (12)
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy$489,533
R01 · FY2023 · CA · contact PI
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy$489,534
R01 · FY2022 · CA · contact PI
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy$1,032,791
R01 · FY2021 · CA · contact PI
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy$286,955
R01 · FY2020 · CA · contact PI
Mechanisms of treatment failure in chimeric antigen receptor T cell therapy$583,532
R01 · FY2019 · CA · contact PI
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$379,044
R01 · FY2018 · CA
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$379,044
R01 · FY2017 · CA
Pretargeted Radioimmunotherapy of CD20+ Lymphomas$383,270
R01 · FY2016 · CA
Optimization of adoptive immunotherapy with autologous CD20-specific T cells$171,720
K23 · FY2016 · CA · contact PI
Optimization of adoptive immunotherapy with autologous CD20-specific T cells$171,720
K23 · FY2015 · CA · contact PI
Optimization of adoptive immunotherapy with autologous CD20-specific T cells$171,720
K23 · FY2014 · CA · contact PI
Optimization of adoptive immunotherapy with autologous CD20-specific T cells$171,720
K23 · FY2013 · CA · contact PI